- Home
- OVID vs STRO Comparison
OVID vs STRO Comparison
Compare OVID & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- STRO
- Stock Information
- Founded
- OVID 2014
- STRO 2003
- Country
- OVID United States
- STRO United States
- Employees
- OVID N/A
- STRO N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OVID Health Care
- STRO Health Care
- Exchange
- OVID Nasdaq
- STRO Nasdaq
- Market Cap
- OVID 88.9M
- STRO 74.3M
- IPO Year
- OVID 2017
- STRO 2018
- Fundamental
- Price
- OVID $1.27
- STRO $0.90
- Analyst Decision
- OVID Strong Buy
- STRO Hold
- Analyst Count
- OVID 4
- STRO 7
- Target Price
- OVID $3.13
- STRO $1.97
- AVG Volume (30 Days)
- OVID 1.5M
- STRO 598.8K
- Earning Date
- OVID 11-11-2025
- STRO 11-12-2025
- Dividend Yield
- OVID N/A
- STRO N/A
- EPS Growth
- OVID N/A
- STRO N/A
- EPS
- OVID N/A
- STRO N/A
- Revenue
- OVID $6,651,000.00
- STRO $104,473,000.00
- Revenue This Year
- OVID $708.13
- STRO $65.42
- Revenue Next Year
- OVID N/A
- STRO N/A
- P/E Ratio
- OVID N/A
- STRO N/A
- Revenue Growth
- OVID 1070.95
- STRO N/A
- 52 Week Low
- OVID $0.24
- STRO $0.52
- 52 Week High
- OVID $1.47
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- OVID 55.01
- STRO 49.24
- Support Level
- OVID N/A
- STRO $0.85
- Resistance Level
- OVID $1.35
- STRO $1.01
- Average True Range (ATR)
- OVID 0.10
- STRO 0.08
- MACD
- OVID -0.07
- STRO -0.01
- Stochastic Oscillator
- OVID 93.78
- STRO 13.67
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.